The chemokine CXCL10 is produced by many inflammatory cells found in the diseased lung and has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). The present study demonstrates elevated CXCL10 protein in the lungs of COPD patients, which appears histologically in airway smooth muscle (hASM). In primary cultured hASM cells taken from normal donors, CXCL10 protein expression was induced by IFN-γ and TNF-α, cytokines reported as elevated in COPD, and a synergistic response was obtained when they were combined. TNF-α stimulation of hASM enhanced accumulation of CXCL10 mRNA, indicating regulation at the transcriptional level, while IFN-γ stimulation resulted in a smaller accumulation of CXCL10 mRNA. When these cytokines were applied simultaneously, an additive effect was obtained. TNF-α-induced CXCL10 expression in hASM was dependent on NFκB activation, and a salicylanilide NFκB inhibitor blocked the CXCL10 expression. In contrast, IFN-γ stimulation resulted in transient NFκB activation, and the inhibitor had little effect on CXCL10 expression. When these cytokines were added simultaneously, NFκB was activated earlier and lasted longer, and the effect was blocked by the inhibitor. These data demonstrate a potential active role for hASM in pulmonary inflammatory diseases such as COPD by producing CXCL10.
CXCL10 [interferon-γ-inducible protein-10 (IP-10)] is a member of the C-X-C chemokine subfamily (2) that was first discovered because it was dramatically upregulated when monocytic cell lines were stimulated with recombinant IFN-γ (3). It is now recognized that CXCL10 is made by a variety of cell types found in the inflamed lung, including neutrophils (4), lymphocytes (5) , and bronchial epithelial cells (6) . Although IFN-γ is able to induce CXCL10 expression in all cells studied (7) (8) (9) (10) (11) , only some of these cells express CXCL10 in response to TNF-α. For example, TNF-α induces CXCL10 expression by endothelial cells (12) but not by TNF-α-stimulated human neutrophils, peripheral blood mononuclear cells (4) , or bronchial epithelial cells (6) . These data suggest differential regulation of CXCL10 expression by IFN-γ and TNF-α based on cell type. Expression of CXCL10 was reported to be synergistically enhanced when both IFN-γ and TNF-α are present in some tissues found outside of the lungs, such as keratinocytes (10) , kidney (13) , and glial cells (14, 15) . These studies demonstrated that this synergistic effect was dependent on the presence of an interferon-stimulated response element (ISRE) as well as an ISRE-proximal NFκB binding site within the CXCL10 promoter region. The specific mechanisms involved with the regulation of CXCL10 expression in the lung are not known.
The CXCR3 ligand CXCL10 stands out among many other chemokines in that it holds a high degree of specificity for attracting activated T lymphocytes. This specificity is achieved through interaction with the CXCR3 receptor, whose other ligands, interferon-γ-inducible T cell chemoattractant (CXCL11, I-TAC) and monokine induced by interferon-γ (CXCL9, Mig), are also CXCR3 specific. CXCR3 expression among inflammatory cells is highly limited to activated, as opposed to resting, T lymphocytes. In particular, CXCR3 is highly expressed on those T lymphocytes that have differentiated to express the Th1 (CD4+) or Tc1 (CD8+) phenotype (16) (17) (18) , suggesting that CXCL10 might be involved in the specific recruitment of effector T lymphocytes to sites of inflammation. CXCL10 also appears to be important for leukocyte adhesion and diapedesis, as CXCR3 stimulation increases T lymphocyte attachment to activated vascular endothelium (19) . The expression of CXCL10 by activated bronchial epithelial cells and neutrophils, combined with the selective expression of CXCR3 on Th1/Tc1 T lymphocytes implicates the chemokine/receptor pair in the pathogenesis of a variety of Th1/Tc1 type T lymphocyte mediated diseases, such as COPD.
COPD is an imprecise term that encompasses a variety of progressive health problems including chronic bronchitis, chronic bronchiolitis, and emphysema, and it is a major cause of mortality and morbidity in the world. Smoking is the major risk factor for the development of COPD. Nearly 50 million people in the United States alone smoke cigarettes, and an estimated 3,000 people take up the habit daily. Thus, COPD is expected to rank among the top five as a worldwide health burden by the year 2020 (20) .
Exposure to cigarette smoke promotes significant damage to airway tissue, resulting in cellular activation and release of inflammatory mediators. Chronic pulmonary inflammation exists in the lungs of patients with COPD and is made up of T lymphocytes (21) , neutrophils, and macrophages (22, 23) . The CD8+ Tc1 type T lymphocytes have been implicated as key culprits in the pathogenesis, especially tissue remodeling, seen in COPD (24, 25) . The T lymphocytes found in the lungs of patients with COPD have been reported to be CXCR3+ (21) . Recently, elevated expression of both CXCR3 and CXCL10 have been demonstrated by immunohistochemistry in the peripheral airways of patients with COPD who smoke (26) . However, it is not known whether CXCL10 exists at pathophysiologically relevant levels in these patients, what cell types might be responsible for CXCL10 production, and how CXCL10 expression might be regulated in COPD.
It is well documented that the activated airway epithelium participates in the pulmonary inflammatory response by producing a variety of mediators, including CXCL10. Recently, airway smooth muscle has also been shown to play a role in the inflammatory process by producing a variety of cytokines and chemokines, including CXCL8 (IL-8; ref 27 ) and CCL5 (RANTES; ref 28) , in response to a variety of stimuli. However, it is not known whether human airway smooth muscle (hASM) can express CXCL10. In the present study, we sought to determine whether the airway tissue itself might participate in the pulmonary inflammatory response in COPD by producing CXCL10. We evaluated CXCL10 expression histologically in lung tissue obtained from COPD patients at autopsy and CXCL10 protein and mRNA expression by primary cultured hASM stimulated with inflammatory cytokines commonly associated with the pathogenesis of COPD (IFN-γ and TNF-α; refs 23, 29, 30) . Finally, we asked whether the transcription factor, NF-κB, might play a role in the regulation of CXCL10 expression by hASM.
METHODS

Analysis of CXCL10 protein concentration in whole lung homogenates from human donors
Human lungs were obtained at autopsy via the National Disease Research Interchange. "Normal" lungs were defined as nonsmokers who did not have any reported chronic disease (Table 1) ; at the time of death, eight were not taking any regular medication, and one was taking an antidepressant. The requirements for inclusion in the "COPD" group were that the donor smoked more than one pack per day for 5 yr or more and had been diagnosed with COPD by a physician at the time of death (Table 1) . COPD diagnosis was also confirmed histologically. Data on pulmonary function were not available; however, seven of the nine patients were also diagnosed with emphysema (which was confirmed by gross visualization as well as by histological analysis), suggesting abnormal pulmonary function. For each gram (wet weight) of tissue, 3 ml of PBS were added. Samples were homogenized and centrifuged at 2000 rpm for 30 min. The supernatant was removed and CXCL10 protein was measured by ELISA assay following the protocol supplied by the manufacturer (R&D Systems, Minneapolis, MN).
Identification of CXCL10 protein by immunohistochemistry
Sections of human lung were obtained at autopsy from human donors (COPD and normal) and snap-frozen. Sections (6 µ) were cut and mounted on glass slides using the CryoJane system (Instrumedics, Hackensack, NJ). Sections were fixed with 100% acetone, rinsed with PBS, and incubated with blocking buffer (PBS containing 0.3% Triton-X-100 and 5% horse serum) for 30 min. Cells were then stained using monoclonal anti-CXCL10 Ab (1:100, diluted in blocking buffer, PeproTech, Rocky Hill, NJ) at 4°C for 24 h in a humidified chamber followed by the Vecta Elite ABC and DAB systems (Vector Laboratories, Burlingame, CA) as described by the manufacturer. Slides were visualized with a light microscope using the x20 objective.
Culture of primary hASM
hASM cultures were prepared using an established protocol (28 Confirmation of smooth muscle cell purity was examined by immunofluorescent staining for smooth muscle α-actin (data not shown). Cultures were maintained at 37°C in a CO 2 incubator.
Identification of CXCL10 protein by ELISA
The hASM were plated in a 24-well plate and grown until confluent. Cells were serum-starved overnight and then treated for 24 h with either recombinant human IFN-γ (0.01-10 ng/ml, PeproTech, Rocky Hill, NJ), TNF-α (0.01-10 ng/ml, PeproTech), or both simultaneously at the same concentration. In some experiments, an NF-κB inhibitor, 5-bromo-N-(3,4-dichlorophenyl)-2-hydroxy-benzamide (salicylanilide analog, 0.1-10 µM), was added to the wells for 30 min before the addition of the cytokines (31) . In time-course experiments, 10 ng/ml of IFN-γ, TNF-α, or both were added, and cell-conditioned media were collected at 1, 5, 8, 15, 18, 22, 24, 32 , and 48 h. CXCL10 in conditioned media was then quantified by ELISA.
Identification and relative quantitation of CXCL10 and CXCR3 mRNA
TaqMan™ (Applied Biosystems) was used to quantify the amount of CXCL10 mRNA in total RNA isolated from stimulated hASM cultures. Primary cultures of hASM were grown until confluent in 6-well tissue culture plates and serum starved overnight. The cells were stimulated with 10 ng/ml of either IFN-γ, TNF-α, or both (each at 10 ng/ml). At 4 h, the cells were harvested and RNA was extracted using Qiagen RNeasy and Qiashredder (Qiagen, Valencia, CA) according to the instructions provided by the manufacturer. RNA was quantified and an RT-PCR reaction was carried out using 200 ng RNA, 10 µl 10X TaqMan RT Buffer, 22 µl 25 mM MgCl 2 , 20 µl 10 mM dNTP mix, 5 µl random hexamers, 2 µl RNase inhibitor, 2.5 µl Multiscribe RT, and water to 100 µl. The following conditions were employed for the PCR reaction using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA): 10 min at 25°C, 30 min at 48°C, and 5 min at 95°C. TaqMan was carried out according to the protocol included with the reagents. The data was analyzed using the comparative threshold cycle (C T ) method for relative quantitation described by the manufacturer for the ABI PRISM 7700 Sequence Detection System. C T is dependent on the starting template copy number and cleavage of the TaqMan fluorogenic probe.
RT-PCR was employed to identify and visualize CXCL10 and CXCR3 mRNA. RNA was isolated as described above. Primers for CXCL10 were obtained from Biosource (Camarillo, CA). For CXCL10, the primers used were: 5′CGC-AAG-CTT-CGC-GAG-ACA-TTC-CTC-AAT-TGC-3′
(sense) and 5′CGC-GGA-TCC-AGG-AGA-TCT-TTT-AGA-CAT-TTC-3′(antisense). A RETROscript kit (Ambion Austin, TX) was used, and the method described by the manufacturer was followed. Amplification cycle times were as follows: denaturing at 94°C for 4 min, then 30 cycles of: 94°C for 30 s, 58°C for 30 s, 72°C for 1 min, and then a final extension at 72°C for 5 min. For CXCR3, Cytopress Quantative PCR Detection Kit for human CXCR Chemokine Receptors (Biosource) was used. This kit contains a mix of primers for CXCR1, CXCR2, CXCR3 and CXCR4. Reactions and amplifications were carried out according to the manufacturer's instructions. Each sample (8 µl) was loaded with 2 µl of loading buffer on a 2% SeaKem Gold agarose gel (BMA, Rockland, MD) and visualized on an Alpha Imager 2200 (Imgen Technologies, Alexandria, VA).
Analysis of NF-κB activation
To measure NF-κB activation, primary cultured hASM cells were stimulated over time with IFN-γ (10 ng/ml), TNF-α (10 ng/ml), or both, and then isolated cells were fractionated into cytoplasmic and nuclear extracts. IκBα was identified in cytoplasmic fractions by SDS-PAGE followed by immunoblot analysis, and p65 was identified by using the p65 TransAm ELISA for transcription activation kit (Active Motif, Carlsbad, CA). Briefly, hASM cells were collected and centrifuged at 1,000 rpm at 4°C for 10 min, washed with 300 µl of PBS, and centrifuged again at 1,000 rpm, 4°C, for 10 min. Cell pellets were used for preparation of cytoplasmic and nuclear extracts following established methods (32, 33) . Protein concentrations were determined using a Bradford kit (Bio-Rad). For immunoblot analysis, cytoplasmic extracts (30 µg protein/lane) were electrophoresed through a 10% SDS gel (Bio-Rad, Hercules, CA). Proteins were transferred to nitrocellulose paper (Amersham-Pharmacia, Piscataway, NJ) for 1 h at 4°C. The blot was incubated with rabbit anti-IκBα antiserum (Santa Cruz Biotechnology, Santa Cruz, CA; 1:500) and then incubated with donkey anti-rabbit horseradish-peroxidase (1:2000, AmershamPharmacia). Immunoreactive bands were visualized using the ECL Western blotting system (Amersham). Nuclear extracts were analyzed for p65 according to the instructions of the manufacturer.
Functional analysis of CXCR3 on hASM
Airway smooth muscle cells were grown in 96-well plates and treated with vehicle (PBS), IFN-γ (10 ng/ml), TNF-α (10 ng/ml), or both. Calcium mobilization studies were carried out using fluo 3-loaded hASM cells in a 96-well plate format using FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, CA) as described previously (34) . Briefly, growth media were removed and cells were incubated with 4 µM fluo 3-AM fluorescent dye indicator (Molecular Probes, Eugene, OR) diluted in Eagle's Minimum Essential Media containing Earl's Salts, 0.1% BSA, and 2.5 mM probenecid (Sigma, St. Louis, MO) for 1 h. Cells were then washed (Krebs Henseleit Ringer with 1 mM Ca ++ , 1 mM Mg ++ , 20 mM HEPES (pH 7.4), 2.5 mM probenecid, and 0.1% BSA), and placed in FLIPR. Agonist was added after 10 s, and concentration-response curves were generated by calculating the maximal fluorescence counts above background for each agonist concentration.
CXCR3 binding studies on hASM
The hASM cells were grown in T-150 flasks and treated with vehicle (PBS), IFN-γ (10 ng/ml), TNF-α (10 ng/ml), or both. Cells were harvested (1x10 6 cells/assay) and competition binding studies were conducted by standard techniques using 125 I-CXCL10 (New England Nuclear, Boston, MA). Samples were incubated with 250 µl of assay buffer [PMI-1640 media with 25 mM HEPES (pH 7.4), 0.1% gelatin (Sigma), 0.1% sodium azide (Sigma)] for 60 min at 25°C. Nonspecific binding was determined in the presence of 1 µM cold CXCL10. Cells were captured on Whatman GF/C filters using a Brandel cell harvester and then washed and counted with 10 ml Beckman Ready Safe (Fullerton, CA). The radioactivity was quantified by scintillation spectrometry.
RESULTS
Measurement of CXCL10 protein in human lung homogenates
To determine whether CXCL10 was upregulated in the lungs of patients with COPD, ELISA was used to measure protein present in homogenates of normal and diseased human lung. CXCL10 levels were significantly higher in the lungs of patients with COPD compared with normal lung tissue (Fig. 1A ). There was a low level of CXCL10, an average of 44.91 ± 6.8 pg/ml in the normal lungs (n=9). The amount of CXCL10 in the lungs of patients with COPD was variable but on average was 361.7 ± 109.1 pg/ml (n=9), which was eightfold higher than that obtained with the normal lungs (P<0.05 vs. "normal").
Identification of CXCL10 protein expression by immunohistochemistry in sections of human lung tissue
Sections of human lung obtained from patients at autopsy were stained for CXCL10. These tissues were from the same patients as those used in the ELISA assay described above. In normal human tissue, no CXCL10 staining was detected (representative section is shown in Fig. 1B,  n=3 ). In tissue harvested from patients diagnosed with COPD at the time of death, histological evaluation was used to confirm a diagnosis of COPD. Significant tissue inflammation, the presence of mucus plugs, alveolar enlargement, fibrotic deposition, and significant carbon deposition could be noted in these sections (data not shown). In addition, seven of the nine patients were diagnosed with emphysema, which was confirmed by gross visualization as well as histological analysis. In COPD patients, CXCL10 was detected primarily in the infiltrating inflammatory cells within the lung parenchyma, in the mucus plug seen in the lumen ("L," representative section is shown in Fig. 1B, n=5) , and in the airway smooth muscle layers ("SM," Fig. 1B) , as indicated by the brown counter stain.
Measurement of CXCL10 protein in cultured hASM stimulated with IFN-γ and TNF-α
Because significant CXCL10 protein was detected in the airway smooth muscle layers in the lungs of patients with COPD, we assessed whether primary cultured hASM could produce CXCL10 in response to TNF-α and IFN-γ. Analysis of hASM conditioned media by ELISA demonstrated that unstimulated cells did not produce detectable basal levels of CXCL10 protein (data not shown). CXCL10 protein was induced in hASM cells treated with IFN-γ in a dosedependent manner ( Fig. 2A) . At 0.1 ng/ml IFN-γ, no CXCL10 protein was detectable, but there were measurable levels of CXCL10 at 1 ng/ml and higher concentrations. CXCL10 was also produced in hASM cells treated with TNF-α in a dose-dependent manner ( Fig. 2A) . At 0.1 ng/ml of TNF-α, there were no significant levels of CXCL10 detectable, but measurable levels of CXCL10 were detectable when the cells were treated with ≥1.0 ng/ml TNF-α.
The hASM cells treated simultaneously with IFN-γ and TNF-α (each added at the same concentration) demonstrated a dramatic increase in the level of CXCL10 produced compared with when the cells were treated with either stimulus alone (Fig. 2B ). Significant levels of CXCL10 protein (516.0±215.3 ng/ml) were obtained when cells were treated concurrently with as little as 0.1 ng/ml of TNF-α and IFN-γ, a concentration where no CXCL10 protein was detectable when cytokines were added individually. The level of CXCL10 detected when IFN-γ and TNF-α were each added at 1 ng/ml simultaneously was significantly greater than that obtained with either stimulus alone, even when each were added at a 10-fold higher dose (10.0 ng/ml).
Both TNF-α and IFN-γ induced CXCL10 expression in hASM, but they appeared to have different times of onset (Fig. 3A) , as assessed by ELISA, and the mode of induction appeared to differ. TNF-α-stimulated cells expressed detectable levels of CXCL10 after 8 h (211.7± 6.3 ng/ml) and reached maximum levels after 36 h (9553±2463 ng/ml). IFN-γ stimulated hASM cells required 18 h to produce detectable levels of CXCL10 (95.3±62.7 ng/ml). However, the levels of CXCL10 continued to increase throughout 48 h (10,039±2,413 ng/ml) and did not level off.
Interestingly, when 10 ng/ml IFN-γ and TNF-α were added together, the CXCL10 levels produced by hASM were large and sustained. CXCL10 was elevated after only 5 h of treatment with both cytokines added simultaneously (7,155±2,363 ng/ml, Fig. 3B ), continued to rise for >24 h and plateaued at 36-48 h.
Visualization and measurement of CXCL10 mRNA by RT-PCR and TaqMan in cultured hASM
PCR experiments showed that CXCL10 mRNA was expressed at low levels in unstimulated hASM cells (Fig. 4A, lane 4) . Fig. 4B ). When IFN-γ and TNF-α were combined, the relative amount of CXCL10 mRNA (delta C T =1.27, Fig. 4B ) was similar to that obtained if the values for TNF-α (delta C T =1.02) and IFN-γ (delta C T =0.123) were added together mathematically (delta C T =1.02+0.123=1.25).
Detection of CXCR3 on hASM by calcium mobilization, radioligand binding, and RT-PCR
Because the hASM secreted significant amounts of CXCL10 in response to stimulation with IFN-γ and TNF-α, we assessed the presence of CXCR3 on stimulated hASM. When a concentration response to CXCL10 was carried out on stimulated hASM using FLIPR to detect CXCR3-stimulated calcium mobilization, none was detected (data not shown) even when applied at 1-33 µM. When radioligand binding studies designed to assess the presence of CXCR3 were carried out using stimulated hASM, there was no specific binding in response to 125 I-CXCL10 (data not shown). Finally, the presence of CXCR3 mRNA in unstimulated (Fig. 4C, lane 5) , TNF-α-stimulated (Fig. 4C, lane 2) , or IFN-γ−stimulated (Fig. 4C, lane 3) hASM was assessed using RT-PCR. No CXCR3 mRNA was detected nor was there message expressed for CXCR1, CXCR2, or CXCR4. In addition, no CXCR3 was detected when hASM were stimulated with TNF-α and IFN-γ simultaneously (Fig. 4C, lane 4) .
Analysis of NF-κB participation in hASM stimulated with IFN-γ and TNF-α
Because NF-κB activation has been reported to be necessary for synergy between TNF-α and IFN-γ in enhancing CXCL10 expression in a variety of tissues, we evaluated whether NF-κB was involved in CXCL10 expression by these cytokines in hASM. Western blot analysis of cytosolic lysates from hASM stimulated with IFN-γ (10 ng/ml) showed a rapid degradation of IκBα (t=15 min) that was not long lasting, as IκBα could be detected in IFN-γ stimulated hASM cell lysates at t = 30 min (Fig. 5A) . These data were confirmed by the presence of p65 in the nuclear lysates of IFN-γ-stimulated hASM cells at t = 15 min that disappeared at t = 30 min (Fig.  6A) . In contrast, TNF-α-stimulated hASM cell lysates did not show IκBα degradation until t = 30 min, which was fully restored by t = 2 h (Fig. 5B) . TNF-α-stimulated hASM nuclear lysates had significant levels of p65 at t = 30 min. The presence of p65 was sustained and could be detected at significant levels for up to 24 h (Fig. 6A) . When IFN-γ and TNF-α were added simultaneously to hASM cell cultures, IκBα degradation could be detected earlier than with TNF-α alone, at t = 0.25 h, and was not fully restored until t = 2 h (Fig. 5C) . Similarly, p65 accumulation in nuclear lysates of simultaneously stimulated hASM cells appeared at t = 0.25 h and was maintained at significant levels up to 24 h (Fig. 6B) .
Analysis of role of NF-κB in TNF-α and IFN-γ stimulated CXCL10 production by hASM cells
Because stimulation of hASM cells with IFN-γ and TNF-α resulted in NF-κB activation and CXCL10 production, we evaluated whether NF-κB was involved in the regulation of CXCL10 expression by IFN-γ and TNF-α. To answer this question, we used a salicylanilide analog inhibitor of NF-κB. This inhibitor acts by inhibiting phosphorylation of IκB and thus binding of NF-κB to a concensus promoter region (31, 35) . The hASM cells were pretreated with the salicylanilide analog (0.03-10 µM) for 30 min and then stimulated with TNF-α, IFN-γ, or both simultaneously (each at 10 ng/ml) for 24 h. Supernatants were collected and tested for the presence of CXCL10 protein by ELISA.
In hASM cells stimulated with 10 ng/ml TNF-α, 10 ng/ml IFN-γ, or both cytokines simultaneously in the absence of the salicylanilide analog inhibitor of NF-κB, CXCL10 protein expression was similar to that seen in previous experiments (TNF-α=1321.7±67.7 pg/ml, IFN-γ=1154.5±11.9 pg/ml, both=12,301.9±352.3 pg/ml, Fig. 7A-C) . In hASM cells stimulated with TNF-α in the presence of the salicylanilide analog, CXCL10 protein expression was inhibited in a dose-related manner (Fig. 7A) . The inhibitory effect of the salicylanilide analog was statistically significant at all concentrations tested, even at the lowest concentration (0.03 µM, P<0.001). At the highest concentration (10 µM), CXCL10 protein production was nearly completely inhibited. In contrast, when hASM cells were stimulated with IFN-γ, the salicylanilide inhibitor did not significantly affect CXCL10 expression at concentrations to 10 µM (Fig. 7B) . In fact, at lower concentrations (0.03-0.3 µM), the inhibitor seemed to slightly potentiate CXCL10 protein synthesis in IFN-γ-stimulated hASM cells. When IFN-γ and TNF-α were added simultaneously in the presence of the NF-κB inhibitor, CXCL10 protein production was inhibited in a concentration-related manner (Fig. 7C) . Inhibition obtained was similar to that when the salicylanilide analog was added in the presence of TNF-α alone. DISCUSSION CXCL10 has been implied in the pathogenesis of COPD (21, 26) ; however the protein has not been reported as having been measured in the lungs of patients with COPD. Data reported here showed that CXCL10 protein levels in the lungs of people who had been diagnosed with COPD at the time of death were elevated eightfold compared with controls. The patient samples used in this study showed a high degree of variability with respect to IP-10 protein levels. These expression levels did not show any correlation with the number of pack years, suggesting that the variability is not related to an effect of smoking. While CXCL10 protein levels were not measured in smokers with out a COPD diagnosis in the present study, Saetta et al. (26) used immunohistochemistry to evaluate CXCL10 expression in the peripheral airways and pulmonary arteries of smokers with normal lung function. They report that CXCL10 is not expressed in these tissues in smokers with normal lung function.
Immunohistochemistry performed on bronchial sections revealed increased expression of CXCL10 the airways of COPD subjects. Importantly, significant CXCL10 expression was detected in the hASM. The CXCL10 receptor, CXCR3, is expressed by activated CD4+ T lymphocytes (helper or memory cells) as well as by CD8+ cytotoxic T lymphocytes (37) (38) (39) , each of which have been implicated in the remodelling events associated with COPD (24) . Stimulation of CXCR3 on lymphocytic cells is thought to facilitate chemotaxis, adhesion, and diapedesis (40) . Thus, in COPD it appears that multiple cell types in the lung, including the airway smooth muscle, act in concert to recruit CXCR3+ T cells to the lungs, leading to a loss of normal lung function.
In light of the novel finding that hASM expresses elevated levels of CXCL10 in the lungs of patients with COPD, we assessed whether stimulation of hASM cells in culture by inflammatory mediators that are important for the pathogenesis of COPD could induce CXCL10 expression. The primary cultured hASM cells expressed CXCL10 protein in a concentration-dependent manner when stimulated with IFN-γ. These data support a vast body of evidence that demonstrates that IFN-γ can induce CXCL10 expression in a variety of cells types, including granulocytes (4), T lymphocytes (41), bronchial epithelial cells (6) , and keratinocytes (10) . In addition, this report demonstrated CXCL10 protein expression increased in hASM cells by stimulation with TNF-α alone. Presently, there is conflicting evidence regarding the ability of TNF-α to induce CXCL10 expression. Whereas TNF-α stimulated vascular endothelial cells secrete CXCL10 (12) , stimulation of human bronchial epithelial cell lines had no effect on CXCL10 expression (6) despite the fact that TNF-α has been shown to be induce expression of other proteins in these cells such as cadherins (42), matrix metalloproteinase-9 (MMP-9 ref 43) , and the chemokine monocyte chemotactic protein-4 (MCP-4, 44). Thus, it appears that the differential regulation of CXCL10 expression by TNF-α may depend on the cell type studied and probably is relative to the type of signaling molecules found in a particular cell.
TNF-α stimulation of hASM cells resulted in significantly elevated accumulation of CXCL10 mRNA, suggesting that this mediator is having an effect on CXCL10 expression at the level of gene transcription. In contrast, stimulation of hASM with IFN-γ resulted in a modest accumulation of CXCL10 mRNA, and the reason for the small increase is unclear. This is possibly a result of a lack of transcriptional upregulation of CXCL10 by IFN-γ, suggesting that the increased levels of CXCL10 protein detected after IFN-γ may be due to regulation at the level of protein translation. Another possibility is that IFN-γ-induced CXCL10 mRNA may not be stable in hASM. IFN-γ has been shown to exert transcriptional regulation over the CXCL10 gene in a variety of other cells studied, resulting in significant CXCL10 mRNA accumulation (7) (8) (9) (10) (11) . Despite this, regulation of the CXCL10 gene by IFN-γ was not observed in hASM.
When IFN-γ and TNF-α were combined, the accumulation of CXCL10 mRNA by hASM was clearly elevated compared with unstimulated cells, or cells stimulated with either cytokine alone, implying an additive effect on transcription of the CXCL10 gene. The level of CXCL10 protein expression was much higher when the hASM cells were treated with both TNF-α and IFN-γ, suggesting a synergistic effect at the translational level. Significant levels of CXCL10 protein (516.0±215.3 ng/ml) were measured when cells were treated simultaneously with 0.1 ng/ml of TNF-α and IFN-γ, whereas little or no CXCL10 protein was detectable at this concentration when each stimulus was added individually. Furthermore, when 10 ng/ml of IFN-γ and TNF-α were added concurrently, significantly elevated concentrations of CXCL10 protein were produced faster by the hASM, after just 5 h of treatment (7,155±2,363 ng/ml). In contrast, no measurable CXCL10 protein was produced until at least 8 h after treatment with TNF-α alone and 18 h after IFN-γ treatment. Taken together, these data suggest that these cytokines, IFN-γ and TNF-α, present in lungs of patients with COPD synergize to produce highly elevated levels of CXCL10.
Because cultured hASM cells secrete CXCL10 protein, we tested whether they also expressed CXCR3, the receptor for CXCL10. Interestingly, IFN-γ and/or TNF-α had little effect on steadystate expression of CXCR3 by cultured hASM, as well as in calcium mobilization assays and radioligand binding studies designed to show the presence of functional CXCR3 receptors on hASM. These data support previously published reports that CXCR3 is expressed preferentially on activated T lymphocytes. (16) . Curiously, Wang et al. (45) demonstrated CXCL10-induced migration and proliferation of carotid arteriole smooth muscle. A receptor other than CXCR3 that is activated by CXCL10 has recently been demonstrated with cellular functional studies on epithelial and endothelial cells (46) . The results of this study suggest that this "non-CXCR3 CXCL10 receptor" is not present on hASM, because we were not able to demonstrate a CXCL10-stimulated calcium mobilization response or specific CXCL10 radioligand binding.
Data reported here showed that when hASM cells were stimulated with TNF-α and IFN-γ simultaneously, a synergistic effect was seen on CXCL10 protein expression. A synergistic effect on protein expression was demonstrated by these two cytokines before, and this synergy has been shown to be at least in part dependent on NF-κB activation and binding to an NF-κB binding site within the CXCL10 promoter (10, (13) (14) (15) . Thus, we asked whether NF-κB might be activated after stimulation of hASM with IFN-γ and TNF-α. There was significant activation of NF-κB when hASM cells were stimulated with TNF-α. These data support a large body of evidence demonstrating that TNF-α receptor stimulation leads to activation of NF-κB (47, 48) . In contrast, IFN-γ stimulation of hASM resulted in only a short pulse of NF-κB activation, indicating that NF-κB is not the primary transcription factor activated by IFN-γ stimulation. More likely, IFN-γ activates receptors coupled to STAT-1 that binds at the ISRE enhancer site within the promoter of the IFN-γ-sensitive gene. (49) . The CXCL10 promoter contains such an ISRE site (14) . Curiously, when the salicylanilide NF-κB inhibitor was added at low concentrations (0.03-0.3 µM) to IFN-γ-stimulated hASM cells, CXCL10 protein expression appeared to be somewhat elevated. The mechanism underlying this potentiation is not known; however, the inhibitor may have affected a negative regulator of protein synthesis independent of IκB. When IFN-γ and TNF-α are added simultaneously, NF-κB was activated earlier (at t=0.25 h), and was sustained for up to 24 h. Thus despite the fact that IFN-γ did not appear to utilize the NF-κB regulatory pathway, the presence of both IFN-γ and TNF-α did have an enhancing effect on NF-κB activation.
Suprisingly, although the salicylanilide analog inhibitor of NF-κB did not inhibit IFN-γ-induced CXCL10 expression, it inhibited CXCL10 production when cells were stimulated by IFN-γ and TNF-α. Taken together, these data suggest that while IFN-γ and TNF-α may work individually through disparate signaling pathways to stimulate CXCL10 secretion, together these cytokines appear to enhance transcription of the CXCL10 gene in an NF-κB-dependent manner. The results support the hypothesis that the synergistic effect of TNF-α and IFN-γ depends on simultaneous activation and binding of ISRE and NF-κB within the CXCL10 promoter region.
In summary, the present study demonstrates that elevated levels of CXCL10 exist in the airways of patients with COPD. Although it is evident that a variety of cell types, especially inflammatory cells, secrete CXCL10, we show that the airway smooth muscle can serve as a source of CXCL10 in inflamed airways. IFN-γ and TNF-α, cytokines associated with the pathogenesis of COPD, alone and in combination, induce CXCL10 secretion. Additionally, NF-κB is shown to play a significant role in the regulation of CXCL10 expression by TNF-α, a minor role in IFN-γ induced CXCL10 expression, but a pivotal role for the synergistic effect of TNF-α and IFN-γ on CXCL10 expression in airway smooth muscle. Collectively, our data for the first time suggest that hASM may be a source of CXCL10, which may play an important role in the pathogenesis of COPD and can serve as a target for pharmacological intervention in the treatment of this condition. protein in homogenates of human lung obtained from patients at autopsy was measured by ELISA as described in Materials and Methods. Each point is the measurement from an individual patient. B) Expression of CXCL10 protein in sections of human lung. CXCL10 protein was detected by immunohistochemistry using a horseradish peroxidaseconjugated staining method as described in Materials and Methods (n=3 for normals; n=5 for COPD). Sections are stained with a monoclonal antibody against human CXCL10 (brown) and counter-stained with hematoxilin (purple). SM, smooth muscle; L, lumen. 
